
MANE
Veradermics is a late-stage biopharmaceutical company developing VDPHL01, an oral extended-release formulation of minoxidil for treating androgenetic alopecia (hair loss) in men and women. The company is positioning VDPHL01 as a non-hormonal alternative designed to improve upon existing treatments by offering faster hair growth, better consistency, and fewer cardiac side effects compared to currently available options. Veradermics is currently conducting a registration-directed clinical program with pivotal trials intended to support FDA approval applications.